The US cuts challenge African funders and governments to provide new models of PrEP access
Lenacapavir and cabotegravir PrEP supported for use in pregnancy and breastfeeding
Scaling back PEPFAR will leave 700,000 without PrEP and cause 6700 new HIV infections within a year
Once-monthly oral PrEP moves into late-stage trials
Manufacturer’s plans for equitable access to twice-yearly PrEP under fire
HIV testing requirements must be simplified for injectable PrEP to have a future
Simpler PrEP services – fewer check-ups, online care – work as well as the standard approach
HIV acquisition in women with good adherence to TAF/FTC PrEP is rare
Injectable PrEP use leads to zero new HIV infections among gay, trans and non-binary Brazilians
